Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... completed the acquisition of leading OTC brands from GSK ... The transaction is a clear demonstration of Perrigo,s unique ... European distribution network spanning 36 countries.  ... commented, "We are excited to complete this transaction, ...
(Date:8/28/2015)... ANDOVER, Massachusetts y LONDRES, 28 de ... PHG, AEX: PHIA) anunció hoy su participación en ... donde exhibirá sus soluciones cardiológicas más recientes y ... IntelliSpace Cardiovascular, que conectan a las personas y ... forma de ayudar a diagnosticar, guiar los tratamientos ...
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2
... N.J., Feb. 28, 2012  Quest Diagnostics Incorporated (NYSE: ... information and services, announced that it is scheduled to ... in New York City.  The presentation is scheduled for ... The presentation will be webcast live during ...
... of United BioSource Corporation (UBC), announced today a new ... patient reported outcomes, a crucial element in the drug ... (ePRO) Consortium, a program run by the Critical Path ... committed to advancing the quality, practicality, and acceptance of ...
Cached Medicine Technology:Bracket Joins ePRO Consortium, a Program of the Critical Path Institute 2Bracket Joins ePRO Consortium, a Program of the Critical Path Institute 3
(Date:8/31/2015)... ... August 31, 2015 , ... Thermi, a ... is proud to announce South Korea’s Ministry of Food and Drug Safety ... most sought-after radio frequency thermotherapy technology available in United States, South Korea, Thailand, ...
(Date:8/30/2015)... ... August 30, 2015 , ... ProTrailer Party is a new and exciting ... 30 styled and detailed presets, allowing FCPX users to immerse the audience into ... will help film makers save time while adding professional titles to every project. , ...
(Date:8/30/2015)... ... 2015 , ... Intellitec Solutions, based in Wilmington, DE, will ... & 6th in San Antonio, TX. Dedicated to bringing long term and post-acute ... over the country come to share the latest and greatest in healthcare technologies, ...
(Date:8/30/2015)... ... 30, 2015 , ... Lizzie’s Lice Pickers , a company that offers ... is currently offering lice head checks for just $10, which is a significant discount ... discount on their lice treatment products. “With kids returning to school, it is very ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and skin ... skin care experience having spent the last 25 years working in operations, purchasing ...
Breaking Medicine News(10 mins):Health News:Thermi Heats Up South Korea Announcing Global Expansion with NewRegulatory Approvals for ThermiRF™ 2Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2
... 21 Meridian International,Center today announced that its ... M.D. will lead Meridian,s new Global Health,Program. The ... of Meridian,s,programs that include world affairs public briefings ... and arts and,cultural activities., "Today, 79% of ...
... SinoFresh HealthCare,Inc. (OTC Bulletin Board: SFSH), a ... today announced that the company,s CEO,Charles Fust, is ... Show., The interview gives viewers an overview ... latest press release., To ...
... It means different things to youngsters, so sex ed ... THURSDAY, Aug. 21 (HealthDay News) -- One reason why ... activity is because abstinence can mean different things to ... University of Washington study. , Teens, attitudes and intentions ...
... vaccination leading to increase, CDC report says , , THURSDAY, ... vaccinate children seems to be behind the highest rate ... Thursday. , Between Jan. 1 and July 31 of ... the United States, many of them among children whose ...
... League Baseball World Series, CHICAGO, Aug. 20 ... the winner of its annual slogan contest today,and ... coaches and parents,about tobacco addiction and the health ... tobacco. This year,s slogan contest winner is,Joe Reck, ...
... recently enacted Medicare Improvement Law immediately affects the operations ... ... nationwide, PORTLAND, Ore., Aug. 20 ... 6331, creating new legislation,protecting Medicare beneficiaries, they also established stricter,requirements for ...
Cached Medicine News:Health News:Former U.S. Assistant Surgeon General, Dr. Susan Blumenthal, to Lead Meridian International Center's Global Health Program 2Health News:[video] Charles Fust, CEO of SinoFresh HealthCare, Inc. Discusses Preliminary Test Results From In Vivo Pilot Study on WallSt.net's 3-Minute Press Show 2Health News:Abstinence-Only Programs Fall Short of Teens' Needs 2Health News:Measles Cases Highest Since 1996 2Health News:Measles Cases Highest Since 1996 3Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:Medicare Advantage Plans Struggle to Comply With New Federal Law 2
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
2 mm tip....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Medicine Products: